Ranibizumab治疗继发于AMD以外的脉络膜新生血管的临床观察  

Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration

作　　者：闾雯娟[1] 肖云[1] 冀垒兵[1] 范银波[1] 蔡岩[1] 

机构地区：[1]解放军第474医院眼科医院,新疆乌鲁木齐830013

出　　处：《现代生物医学进展》2014年第26期5135-5138,5108,共5页Progress in Modern Biomedicine

摘　　要：目的:探讨Ranibizumab治疗继发于年龄相关性黄斑变性(AMD)以外的脉络膜新生血管的安全性和有效性。方法:回顾性分析55例55眼临床确诊为非AMD的CNV患者,其中包括高度近视40眼,中渗15眼,每月行玻璃体腔注射Ranibizumab,依据眼底检查、OCT情况决定是否重复注射。随访6个月,对比分析治疗前后患者最佳矫正视力(BCVA)、FFA、OCT等检查结果的变化。结果:注射雷珠单抗均无严重的眼部或相关的全身不良事件,平均注射2.46次,治疗前及末次随访时BCVA分别是0.079±0.264、0.638±0.290,视物变形明显减轻,差异有显著统计学意义(P<0.001);治疗前及末次随访时黄斑中心厚度分别是(468.637±126.796)μm、(237.764±76.48)μm,差异有显著统计学意义(P<0.001)。治疗前FFA显示有CNV及荧光渗漏,治疗后新生血管萎缩,无荧光渗漏,治疗前后眼压差异无统计学意义(P>0.05)。结论:每月玻璃体腔注射Ranibizumab,病情稳定后PRN给药,在治疗继发于AMD以外的CNV方面,是一种安全、有效的治疗方法。Objective： To explore the safety and efficacy ofranibizumab for the treatment of choroidal neovascular-ization （CNV） secondary to causes outside the age-related macular degeneration （AMD）. Methods： Retrospective analysis of the clinical diagnosis of 55 cases 55 eyes of patients with CNV outside AMD, including pathologic myopia （PM） 40 eyes, CSC 15 eyes. All parents were monthly intravitreal injections ranibizumab, whether to repeat the injection decide on the basis of fundus examination, OCT. Patients were followed up for 6 months.Best-corrected visual acuity （BCVA）, fundus fluorescein angiography （FFA）, optical coherence tomography （OCT）were Comparative analysis before and after treatment. Results： No serious ocular or systemic adverse events related to ranibizumab or the injection procedure were reported. Patients received an average of 2.46 injections.Before injection, the mean BCVA was 0.079± 0.264, which impoved to 0.638±0.290 at the last reexamination, respectively, there were significant differences（P〈0.001）; Before treatment central macular thickness is （468.637±26.796）μm, and it＇s （237.764± 76.48） μm at the end of the follow-up, respectively,there were significant differences （P〈0.001）. FFA demonstrated the choroidal neovascular-ization （CNV） with fluorescence leakage before injection, CNV was atrophy without fluorescence leakage after injection.There was no statistical defference in intraocular pressure before and after injectuin （P〉0.05）. Conclusions： Monthly intravitreal injection of Ranibizumab, PRN administration in stable condition, is the safly and effective method for the CNV due to causes outside AMD.

关 键 词：RANIBIZUMAB 黄斑病变 脉络膜新生血管 玻璃体腔注射 

分 类 号：R56[医药卫生—呼吸系统]